Our next steps.

Funds for initial development of the patent-pending NOVACC device are being raised currently.

To date, the inventor has personally funded NOVACC in order to expedite development, resulting in movement from the initial idea to the current stage in less than six months. 

• An advisory team representing subject matter experts in all areas critical to the development of this device is already in place.

•  With the concept having been vetted, drawings produced, provisional patent protection approved and prototype being produced, there remain pending approvals and costs. This includes NIOSH/FDA approval along with the non-provisional patent application (to be submitted after prototype within the one year provisional patent period, October 2022). 

• Additional costs include incorporation, website development, marketing, distribution and the creation of the production ready prototype, among others. 

Our development timeline.

• Summer 2021 – Presentations to Partners

• October 2021 – Filing of Provisional Patent (63/257,098)

• October 2022 - Filing of Non-Provisional Patent (18/046,964)

• December 2022 - Filing of Non-Provisional Patent (18/092,043)

• October 2021-September 2022 – Georgia Technical Institute develops a prototype of NOVACC. The goal is to design a wearable device that eliminates inhalation and exhalation of live viruses that spread respiratory illnesses, such as COVID and the flu. A secondary goal is to enable the manufacturing of a device that is affordable to the masses at less than $100.

• October 2022 - Non-provisional patent ( 18/046,964) filed

• December 2021 - December 2022 – Raising of initial funding 

• January-December 2022 – Identification of key manufacturing and sales partners

• October 2022 – Prototype in progress. Secure investors, manufacturing and sales partners

• Patents approved:

• 18,092,043

• 63,257,098

• 18,046,964